These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37861217)

  • 61. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Teplizumab: type 1 diabetes mellitus preventable?
    Misra S; Shukla AK
    Eur J Clin Pharmacol; 2023 May; 79(5):609-616. PubMed ID: 37004543
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
    Hensen J; Howard CP; Walter V; Thuren T
    Diabetes Metab; 2013 Dec; 39(6):524-31. PubMed ID: 24075453
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
    Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
    Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study).
    Pozzilli P; Visalli N; Signore A; Baroni MG; Buzzetti R; Cavallo MG; Boccuni ML; Fava D; Gragnoli C; Andreani D
    Diabetologia; 1995 Jul; 38(7):848-52. PubMed ID: 7556988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Gitelman SE; Bundy BN; Ferrannini E; Lim N; Blanchfield JL; DiMeglio LA; Felner EI; Gaglia JL; Gottlieb PA; Long SA; Mari A; Mirmira RG; Raskin P; Sanda S; Tsalikian E; Wentworth JM; Willi SM; Krischer JP; Bluestone JA;
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):502-514. PubMed ID: 34214479
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    Ware J; Allen JM; Boughton CK; Wilinska ME; Hartnell S; Thankamony A; de Beaufort C; Schierloh U; Fröhlich-Reiterer E; Mader JK; Kapellen TM; Rami-Merhar B; Tauschmann M; Nagl K; Hofer SE; Campbell FM; Yong J; Hood KK; Lawton J; Roze S; Sibayan J; Bocchino LE; Kollman C; Hovorka R;
    N Engl J Med; 2022 Jan; 386(3):209-219. PubMed ID: 35045227
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol.
    Boughton C; Allen JM; Tauschmann M; Hartnell S; Wilinska ME; Musolino G; Acerini CL; Dunger PD; Campbell F; Ghatak A; Randell T; Besser R; Trevelyan N; Elleri D; Northam E; Hood K; Scott E; Lawton J; Roze S; Sibayan J; Kollman C; Cohen N; Todd J; Hovorka R;
    BMJ Open; 2020 Mar; 10(3):e033500. PubMed ID: 32169925
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
    Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
    Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD)--a study protocol for a pilot randomized controlled trial.
    Lascar N; Kennedy A; Jackson N; Daley A; Dowswell G; Thompson D; Stokes K; Greenfield S; Holder R; Andrews R; Narendran P
    Trials; 2013 Jun; 14():180. PubMed ID: 23777480
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
    Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
    N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.
    Tooley JE; Vudattu N; Choi J; Cotsapas C; Devine L; Raddassi K; Ehlers MR; McNamara JG; Harris KM; Kanaparthi S; Phippard D; Herold KC
    Eur J Immunol; 2016 Jan; 46(1):230-41. PubMed ID: 26518356
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.
    Demeester S; Keymeulen B; Kaufman L; Van Dalem A; Balti EV; Van de Velde U; Goubert P; Verhaeghen K; Davidson HW; Wenzlau JM; Weets I; Pipeleers DG; Gorus FK
    Diabetes Care; 2015 Apr; 38(4):644-51. PubMed ID: 25583753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
    Lazar L; Ofan R; Weintrob N; Avron A; Tamir M; Elias D; Phillip M; Josefsberg Z
    Diabetes Metab Res Rev; 2007 May; 23(4):286-91. PubMed ID: 17124721
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 80. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.